Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Pipeline Review, H1 2019
Summary
Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Receptor tyrosineprotein kinase erbB3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosineprotein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin1 NRG1 and is activated by it. It also activated by CSPG5.
Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Breast Cancer, NonSmall Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Solid Tumor, Esophageal Cancer, Head And Neck Cancer, Lung Cancer, Gallbladder Cancer, Gastroesophageal GE Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Bile Duct Cancer Cholangiocarcinoma, Biliary Tumor, Carcinoma of Unknown Primary Occult Primary Tumor/Cancer of Unknown Primary, Endometrial Cancer, Epithelial Tumor, Hypopharyngeal Cancer, Laryngeal Cancer, Lung Adenocarcinoma, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma HCC, Oral Cavity Mouth Cancer, Oropharyngeal Cancer, Papillary Thyroid Cancer, Paranasal Sinus And Nasal Cavity Cancer, Sarcomas, Squamous Cell Carcinoma, Squamous NonSmall Cell Lung Cancer, Thyroid Cancer and Transitional Cell Cancer Urothelial Cell Cancer.
The latest report Receptor Tyrosine Protein Kinase ERBB 3 Pipeline Review, H1 2019, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1
The report reviews Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope